^
    Back
    Association details:
    Biomarker:NANOGNB mutation
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2021
    Title:

    691P - Effect of NANOGNB mutations on DNA damage response and efficacy of immune checkpoint inhibitors in advanced renal clear cell carcinoma

    Published date:
    09/13/2021
    Excerpt:
    NANOGNB-MUT was strongly associated with higher ORR, better DCB, longer PFS in advanced ccRCCs in ICIs.